普罗基尼克斯制药

美股公司 · 2018年11月27日 · 25 次阅读

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

公司基本面

市值 450.56M 市盈率 0.0
当前价 5.20 目标价 12.25
ROI -44.60% ROE -73.70%
ROA -36.40% RSI 45.06
指标说明
市盈率 = 股价/年度每股收益:
  • <0 :指该公司盈利为负(计算市盈率没有意义,一般显示为“—”)
  • 0-13 :即价值被低估(一般传统行业 或者周期性行业的股票都比较低 比如美光科技)
  • 14-20:即正常水平
  • 21-28:即价值被高估
  • 28+ :反映股市出现投机性泡沫
市净率 = 总市值/所有者权益:

一般市净率较低的股票, 投资价值较高

资产收益率(ROA) = 净利润/总资产:

该指标越高 表示公司资产利用效果越好

净资产收益率(ROE) = 净利润/总股东权益:

该指标越高 表示投资带来的收益越高

普罗基尼克斯制药 公司 评级升降级

日期 机构 评级 目标价
18-09-14 Needham 降级 Strong 购买 → 购买 $16 → $12
18-08-01 Needham 重申 Strong 购买 $14 → $16
17-02-06 Needham 升级 购买 → Strong 购买 $11 → $14
16-10-27 Aegis Capital 启动 购买
15-10-23 Jefferies 升级 持有 → 购买
15-08-07 Needham 重申 购买 $9 → $11
15-08-06 Brean Capital 重申 购买 $11 → $14
14-02-03 Needham 升级 持有 → 购买 $8
12-08-30 Stifel Nicolaus 启动 持有
12-07-30 Needham 降级 购买 → 持有
11-02-10 Brean Murray 升级 持有 → 购买 $13
09-10-14 Needham 降级 购买 → 持有
09-05-12 RBC Capital Mkts 重申 跑赢市场 $14 → $12
09-03-16 Brean Murray 降级 购买 → 持有
09-03-16 RBC Capital Mkts 重申 跑赢市场 $21 → $14
09-03-16 Oppenheimer 降级 跑赢市场 → Perform
09-03-12 FTN Equity Capital 启动 中立
08-08-11 RBC Capital Mkts 重申 跑赢市场 $19 → $21
08-07-02 Friedman Billings 降级 Mkt Perform → Underperform $9 → $12
08-06-06 Ladenburg Thalmann 重申 购买 $17 → $40

相关问题

互联网券商的港股、美股开户教程

如果您对美股 或者 港股也感兴趣, 或者想要了解如何开户, 可以加我wechat: xiaobei060537, 同时也可以拉您进美股交流群哦。
最后的最后 祝大家都有一个美好的投资生活哦。

大家也可以关注美股指南公众号, 会定期更新一些美股知识哦

写在最后

友情提示 转载请注明出处: https://investguider.com/topics/806
暂无回复。
需要 登录 后方可回复, 如果你还没有账号请点击这里 注册